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There exist many case reports and studies on the antipsychotic augmentation by aripirazole in partial responders to clozapine, the
most seem to be finding a slight diﬀerence in the PANSS and CGI scores after the aripirazole addition. The results of our report
are compatible with those of other studies but, we have found a considerable antianxiety action in both of the cases. The 5HT1A
agonism of aripirazole could be hypothesized as mechanism contributing to this eﬀect.
1. Introduction
Clozapine is the drug of choice in treatment-resistant schiz-
ophrenia, but 40–70% of clozapine-treated patients continue
to demonstrate suboptimal clinical response [1–4].
Various augmentation strategies have been tested, in-
cluding the use of other atypical antipsychotics, but no clear
recommendations can presently be proposed [5–10].
Augmentation with aripiprazole has been documented in
case reports [11], in open trials [5, 12], and in a randomized
controlled study [13].
In this paper, we report on 2 cases in which augmentation
with aripiprazole had a beneficial impact on anxiety.
2. Case Presentation
2.1. Case Report 1. Ms. A, a 40-year-old woman diagnosed
with a residual schizophrenia [14] was admitted following an
exacerbation of psychotic symptoms with a predominance of
anxiety despite 700mg/d of clozapine for two years. The clin-
ical scores and the trough plasma concentrations of clozapine
and norclozapine at admission were CGI : 5; total PANSS:
123; positive: 17/49; negative: 18/49; excited component:
12/35; general: 39/112; Hamilton-anxiety: 14/56; clozapine:
896 ng/mL; norclozapine: 551 ng/mL, respectively (clozapine
therapeutic range: 350–600 ng/mL [15–17]). Because of the
risks of seizures, the dose was reduced to 500mg/d, and
aripiprazole (10mg/d) was added. Clozapine and norcloza-
pine plasma concentrations measured after 10 days were
decreased according to the reduction of the dose (615 ng/mL
and 478 ng/mL, resp.). The aripiprazole plasma concen-
tration after 10 days was 282 ng/mL. Following a clinical
reduction of the anxiety, the patient was discharged from the
hospital three weeks after the addition of aripiprazole.
A followup over 6 months did not reveal any change
in the CGI and PANSS scores (at 6 months: CGI : 5; total
PANSS: 125; positive: 18/49; negative: 23/49; excited com-
ponent 10/35; general: 38/112). On the other hand, the
Hamilton-anxiety score diminished progressively to 12, 7,
and 8 after one, three, and 6 months, respectively. Cloza-
pine and norclozapine plasma levels were stable over this
2 Case Reports in Psychiatry
period (at the sixth month: 608 ng/mL, 443 ng/mL, and
75 kg, resp.), and the comedications (clorazepate 20mg/d,
valsartane 40mg/d, zopiclone 7,5mg/d, and tamsulosine
0.4mg/d) were not modified. No reports are describing an
impact on anxiety by the antihypertensive comedication by
valsartane (an angiotensin II receptor antagonist) and tam-
sulosine (peripheral α1-antagonist). There is no significant
pharmacokinetic or pharmacodynamic interactions of that
comedication and the antipsychotic/anxiolytic treatments.
2.2. Case Report 2. Mr. L, a 48-year-old man with a diagnosis
of residual schizophrenia [14] treated for many years with
clozapine 500mg/d was admitted because of the worsening
of his anxiety. The clinical scores and the trough plasma
concentrations of clozapine and norclozapine were: CGI : 4;
total PANSS: 88; positive: 20/49; negative 25/49; excited
component: 9/35; general 40/112. Hamilton-anxiety: 24/56;
clozapine: 594 ng/mL; norclozapine: 470 ng/mL, respec-
tively. Aripiprazole 10mg/d was added to clozapine (dose
unchanged) and lorazepam (1mg/d) was discontinued. The
patient was discharged three weeks after the aripiprazole
addition.
A followup over 3 months did not reveal any change
in the CGI and PANSS scores (at 3 months: CGI : 4; total
PANSS: 73; positive: 20/49; negative: 25/49; excited com-
ponent: 7/35; general: 40/112), while the Hamilton-anxiety
score diminished progressively to 19 and 15 after one and
three months, respectively. The clozapine and norclozapine
plasma concentrations at three months were 431 ng/mL and
343 ng/mL, respectively.
3. Discussion
In the present paper the augmentation did not result in a
reduction of psychotic symptoms despite a treatment period
of 3 to 6months, which is in agreement with previous reports
[5, 10–13]. Because a therapeutic window has been demon-
strated for clozapine [17, 18], it is important to mention that
therapeutic blood levels of clozapine were maintained during
the whole observation period. An important reduction of
anxiety was clinically observed in both cases, with a marked
improvement of psychosocial functioning observed, which
allowed a change of residential institution of both cases,
three and six months after the discharge from the hospital,
for a residential stay in more open environment with less
psychosocial accompanying measures.
It has been suggested that in anxiety disorders, the
adjunction of atypical antipsychotics to the current SSRI
and/or benzodiazepine treatment could, through the modu-
lation of the dopaminergic system, be beneficial but the data
are not conclusive [19, 20].
The agonist action of aripiprazole on the 5HT1A recep-
tors could eventually contribute to the antianxiety action that
we have observed [21].
However, considering the present observations could be
due to external factors or to the natural evolution of the
illness, a randomized controlled study is required to evaluate
the eﬃcacy of the clozapine-aripiprazole combination in
cases of treatment-resistant schizophrenia with predomi-
nance of anxiety. Moreover, the anxiety observed in Case 1
could have been in part attributable to psychotoxic eﬀects
due to the high plasma concentration at the begining of the
followup [22].
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